Egbert de Jong

Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin

Allan M. Ross, Peter Molhoek, Conor F. Lundergan et al. · Circulation · 2001 · 173 citations · Full text

The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain

Richard Rauck, S. Bookbinder, T. Bunker et al. · Journal of Opioid Management · 2006 · 65 citations · Full text

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)

Victoria Atkinson, Shahneen Sandhu, Geke A.P. Hospers et al. · Melanoma Research · 2020 · 35 citations · Full text

Oncology, Melanoma, Pharmacology +12

Increased Plasminogen Activator Inhibition Levels in Malignancy

Egbert de Jong, E.A.R. Knot, Dick Piket et al. · Thrombosis and Haemostasis · 1987 · 34 citations

A randomized, open-label study of once-a-day AVINZA® (morphine sulfate extended-release capsules) versus twice-a-day OxyContin® (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: The extension phase of the ACTION trial

Richard Rauck, S. Bookbinder, T. Bunker et al. · Journal of Opioid Management · 2006 · 28 citations · Full text